Clinical Data Manager (Needham, MA or New Haven, CT)
Director Clinical Operations (Needham, MA or New Haven, CT)
Patient Recruitment/Clinical Trials Administrator (Needham, MA or New Haven, CT)
Celldex’s primary focus is in oncology. There are four programs currently in clinical development for treatment of multiple cancers. Our lead program, CDX-110, is an experimental therapeutic cancer vaccine that targets the tumor-specific molecule epidermal growth factor receptor variant III (EGFRvIII) in patients with Glioblastoma Multiforme (GBM); CDX-011 is our lead antibody-drug conjugate with potential for development within our Precision Targeted Immunotherapy Platform; and our additional clinical programs, CDX-1307 and CDX-1401, use our APC Targeting Technology™. A number of additional programs using the APC targeting and therapeutic antibody approaches are progressing towards clinical development.